MedTrace Logo

CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab

NCT05564923 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-10-04

No results posted yet for this study

Summary

The Geriatric 8 (G8), Vulnerable Elders Survey (VES-13), and Cancer and Aging Research Group (CARG) questionnaires are among the main tests whose purpose is to predict the risk of chemotherapy-induced toxicity (CRT) and allow treatment. Investigators aimed to investigate the effect of using the G8, VES13, and CARG scales in the geriatric age group in cancer patients receiving nivolumab treatment in predicting side effects.

Conditions

  • Nivolumab Related Toxicity

Interventions

DRUG

there is no intervention

there is no intervention

Sponsors & Collaborators

  • Namik Kemal University

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-02
Primary Completion
2023-06-17
Completion
2023-08-17
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05564923 on ClinicalTrials.gov